ArticleCancer immunology, immunotherapy : CII2014
Clinical evaluation of systemic and local immune responses in cancer: time for integration.
Article in Cancer immunology, immunotherapy : CII, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.Cancer immunology, immunotherapy : CII · 2015Trial
- NIR-IIb fluorescence ratiometric imaging of tumor-associated neutrophils for immunotherapy efficacy monitoring and strategy optimization.Nature communications · 2025Article
- Circulating CD16+ CD56+ Natural Killer Cells in Colorectal Cancer and Their Correlation with Survival.Malawi medical journal : the journal of Medical Association of Malawi · 2025Article
- Tumor-Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies.Children (Basel, Switzerland) · 2025Review
- Molecular probes for in vivo optical imaging of immune cells.Nature biomedical engineering · 2025Review
- NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy.Molecular oncology · 2023Article
- Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine.Nature biomedical engineering · 2023Article
- Article
- Preoperative neutrophil-to-lymphocyte ratio behaves as an independent prognostic factor even in patients with postoperative complications after curative resection for gastric cancer.Langenbeck's archives of surgery · 2022Article
- Spatial variation in gene expression of Tasmanian devil facial tumors despite minimal host transcriptomic response to infection.BMC genomics · 2021Article
- Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.World journal of surgical oncology · 2021Article
- Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft.JCI insight · 2021Article
- Systemic immune responses are associated with molecular characteristics of circulating tumor cells in head and neck squamous cell carcinoma.Molecular and clinical oncology · 2021Article
- In vitro assessment of antitumor immune responses using tumor antigen proteins produced by transgenic silkworms.Journal of materials science. Materials in medicine · 2021Article
- Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.Frontiers in immunology · 2021Review
- Associations between absolute neutrophil count and lymphocyte-predominant breast cancer.Breast (Edinburgh, Scotland) · 2020Article
- Prognostic value of peripheral blood natural killer cells in colorectal cancer.BMC gastroenterology · 2020Article
- Article
- Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants.International journal of molecular sciences · 2019Review
- Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer.Translational oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The immune system has a dual role in cancer development and progression. On the one hand, it can eradicate emerging malignant cells, but on the other hand, it can actively promote growth of malignant cells, their invasive capacities and their ability to metastasize. Immune cells with predominantly anti-tumor functionality include cells of the innate immune system, such as natural killer cells, and cells of adaptive immunity, such as conventional dendritic cells and cytotoxic T lymphocytes. Immune cells with predominantly pro-tumor functionality include a broad spectrum of cells of the innate and adaptive immune system, such as type 2 neutrophils and macrophages, plasmacytoid DC, myeloid-derived suppressor cells and regulatory T lymphocytes. The presence of immune cells with tumor-suppressive and tumor-promoting activity in the cancer microenvironment and in peripheral blood is usually associated with good clinical outcomes and poor clinical outcomes, respectively. Significant advances in experimental and clinical oncoimmunology achieved in the last decade open an opportunity for the use of modern morphologic, flow cytometric and functional tests in clinical practice. In this review, we describe an integrated approach to clinical evaluation of the immune status of cancer patients for diagnostic purposes, prognostic/predictive purposes (evaluation of patient prognosis and response to treatment) and for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.